IL-4 and IL-13 mediated down-regulation of CD8 expression levels can dampen anti-viral CD8+ T cell avidity following HIV-1 recombinant pox viral vaccination

Vaccine

Volumn 31, Issue 41, 2013, Pages 4548-4555

  Wijesundara, Danushka K ^a   Jackson, Ronald J ^a   Tscharke, David C ^b   Ranasinghe, Charani ^a  

^a Australian National University   (Australia)

^b AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

Author keywords

CD8 expression; CD8+ T cell avidity polyfunctionality; HIV 1 vaccines vaccination; IL 4 IL 13; Mucosal vaccination

Indexed keywords

CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; STAT6 PROTEIN; TETRAMER; TUMOR NECROSIS FACTOR ALPHA; VIRUS VACCINE;

ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CELL ADHESION; CELL DENSITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; HUMAN IMMUNODEFICIENCY VIRUS 1; LYMPHOCYTE FUNCTION; MOUSE; NONHUMAN; POXVIRUS INFECTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SPLEEN CELL; VACCINATION; VACCINIA VIRUS;

ANALYSIS OF VARIANCE; ANOVA; BD; BECKTON DICKINSON; CD8 EXPRESSION; CD8(+) T CELL AVIDITY/POLYFUNCTIONALITY; FCS; FETAL CALF SERUM; FOWLPOX VIRUS ENCODING HIV-1 ANTIGENS; FPV-HIV; FPV-HIV OR VV-HIV ENCODING MURINE SOLUBLE IL-13RΑ2; HIV-1 VACCINES/VACCINATION; I.M.; I.N.; I.P.; ICS; IFN; IFN-I; IL; IL-13 INHIBITOR VACCINES; IL-13 RECEPTOR Α 2; IL-13RΑ2; IL-4/IL-13; INTERFERON; INTERLEUKIN; INTRACELLULAR CYTOKINE STAIN; INTRAMUSCULAR; INTRANASAL; INTRAPERITONEAL; LCMV; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MEAN FLUORESCENT INTENSITY; MFI; MUCOSAL VACCINATION; PBS; PEPTIDE-MAJOR HISTOCOMPATIBILITY CLASS I COMPLEXES; PHOSPHATE BUFFER SALINE; PMHC-I; RBC; RED BLOOD CELL; SEM; SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6; STANDARD ERROR OF THE MEAN; STAT6; T CELL RECEPTOR; TCR; TNF; TUMOR NECROSIS FACTOR; TYPE I INTERFERONS; VACCINIA VIRUS ENCODING HIV-1 ANTIGENS; VACCINIA VIRUS WESTERN RESERVE STRAIN; VV-HIV; VV-WR; WILD-TYPE; WT;

ADMINISTRATION, MUCOSAL; AIDS VACCINES; ANIMALS; ANTIGENS, CD8; CD8-POSITIVE T-LYMPHOCYTES; DOWN-REGULATION; FEMALE; HIV-1; INTERLEUKIN-13; INTERLEUKIN-4; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; VACCINES, SYNTHETIC;

EID: 84883600567     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.07.062     Document Type: Article

References (50)

1. Thompson M.A., Aberg J.A., Cahn P., Montaner J.S., Rizzardini G., Telenti A., et al. troviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. Journal of the American Medical Association 2010, 304:321-333.
2. McMichael A.J., Borrow P., Tomaras G.D., Goonetilleke N., Haynes B.F. The immune response during acute HIV-1 infection: clues for vaccine development. Nature Reviews Immunology 2010, 1(10):1-23.
3. McElrath M.J., Corey L., Montefiori D., Wolff M., Schwartz D., Keefer M., et al. A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection AIDS Vaccine Evaluation Group. AIDS Research and Human Retroviruses 2000, 16:907-919.
4. Guimaraes-Walker A., Mackie N., McCormack S., Hanke T., Schmidt C., Gilmour J., et al. Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers. Vaccine 2008, 26:6671-6677.
5. Buchbinder S.P., Mehrotra D.V., Duerr A., Fitzgerald D.W., Mogg R., Li D., et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the step study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008, 372:1881-1893.
6. Kelleher A.D., Puls R.L., Bebbington M., Boyle D., Ffrench R., Kent S.J., et al. A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1. AIDS 2006, 29(20):4-7.
7. McCormack S., Stohr W., Barber T., Bart P.A., Harari A., Moog C., et al. EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine 2008, 316(26):2-74.
8. Rolland M., Tovanabutra S., deCamp A.C., Frahm N., Gilbert P.B., Sanders-Buell E., et al. Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nature Medicine 2011, 17:366-371.
9. Wijesundara D.K., Jackson R.J., Ramshaw I.A., Ranasinghe C. Human immunodeficiency virus-1 vaccine design: where do we go now?. Immunology & Cell Biology 2011, 89:367-374.
10. + T cells is reflected by their avidity, polyfunctionality, and clonal turnover. Journal of Experimental Medicine 2007, 204:2473-2485.
11. Lyons D.S., Lieberman S.A., Hampl J., Boniface J.J., Chien Y., Berg L.J., et al. A TCR binds to antagonist ligands with lower affinities and faster dissociation rates than to agonists. Immunity 1996, 5(5):3-61.
12. Ratnofsky S.E., Peterson A., Greenstein J.L., Burakoff S.J. sion and function of CD8 in a murine T cell hybridoma. Journal of Experimental Medicine 1997, 166:1747-1757.
13. Bierer B.E., Burakoff S.J. T cell adhesion molecules. FASEB Journal 1988, 258(2):4-90.
14. + T cells without selection of higher affinity TCR. Nature Immunology 2001, 2:711-717.
15. Derby M., Alexander-Miller M., Tse R., Berzofsky J. High-avidity CTL. exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL. Journal of Immunology 2001, 166:1690-1697.
16. Wijesundara D.K., Ranasinghe C. Prime-boost vaccines: an overview. Gene Vaccines 2012, 183-204. Springer Wien, New York. Thalhamer (Ed.).
17. Appay V., Douek D.C., Price D.A. CD8+ T cell efficacy in vaccination and disease. Nature Medicine 2008, 62(14):3-8.
18. + T-cell responses in rectal mucosa and peripheral blood mononuclear cells during chronic HIV type 1 infection. Journal of Virology 2007, 81:5460-5471.
19. + T cells. Blood 2006, 478(107):1-9.
20. Berger C.T., Frahm N., Price D.A., Mothe B., Ghebremichael M., Hartman K.L., et al. High-functional-avidity cytotoxic T lymphocyte responses to HLA-B-restricted Gag-derived epitopes associated with relative HIV control. Journal of Virology 2011, 933(85):4-45.
21. Sharma D.P., Ramsay A.J., Maguire D.J., Rolph M.S., Ramshaw I.A. Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxic T-lymphocyte responses and exacerbates vaccinia virus infection in vivo. Journal of Virology 1996, 70:7103-7107.
22. Jackson R.J., Ramsay A.J., Christensen C.D., Beaton S., Hall D.F., Ramshaw I.A. Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. Journal of Virology 2001, 75:1205-1210.
23. Ahlers J.D., Belyakov I.M., Terabe M., Koka R., Donaldson D.D., Thomas E.K., et al. A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:13020-13025.
24. + T-cell avidity and protective immunity. Mucosal Immunology 2013, 10.1038/mi.2013.1.
25. + T cells with regime-dependent cytokine/granzyme B profiles. Journal of Immunology 2007, 178:2370-2379.
26. + T cells correlates with higher quality anti-viral immunity. PLoS ONE 2013, 8:e55788.
27. + CTL avidity. European Journal of Immunology 2009, 39:1819-1830.
28. Ranasinghe C., Medveczky J.C., Woltring D., Gao K., Thomson S., Coupar B.E., et al. Evaluation of fowlpox-vaccinia virus prime-boost vaccine strategies for high-level mucosal and systemic immunity against HIV-1. Vaccine 2006, 24:5881-5895.
29. Kroger C.J., Alexander-Miller.M.A. Dose-dependent modulation of CD8 and functional avidity as a result of peptide encounter. Immunology 2007, 16(122):7-78.
30. Seder R.A., Darrah P.A., Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nature Reviews Immunology 2008, 24(8):7-58.
31. + T cell responses. Journal of Experimental Medicine 2007, 204:1405-1416.
32. Choi E.M., Chen J.L., Wooldridge L., Salio M., Lissina A., Lissin N., et al. High avidity antigen-specific CTL identified by CD8-independent tetramer staining. Journal of Immunology 2003, 511(171):6-23.
33. + T cell responses. European Journal of Immunology 2006, 295(36):1-9.
34. Xiao Z., Mescher M.F., Jameson S.C. Detuning CD8 T cells: down-regulation of CD8 expression, tetramer binding, and response during CTL activation. Journal of Experimental Medicine 2007, (204):2667-2677.
35. + T cells to a poorly cytolytic CD8low phenotype in the presence of IL-4. Journal of Immunology 2005, 174:2021-2029.
36. + T cells. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:17475-17480.
37. Belyakov I.M., Isakov D., Zhu Q., Dzutsev A., Berzofsky J.A. A novel functional CTL avidity/activity compartmentalization to the site of mucosal immunization contributes to protection of macaques against simian/human immunodeficiency viral depletion of mucosal CD4+ T cells. Journal of Immunology 2007, 178:7211-7221.
38. + CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization. Virology 2008, 381:106-115.
39. Belyakov I.M., Hel Z., Kelsall B., Kuznetsov V.A., Ahlers J.D., Nacsa J., et al. Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nature Medicine 2001, 7:1320-1326.
40. + CTLs in delay of AIDS viral dissemination from mucosa. Blood 2006, 107:3258-3264.
41. Kent S.J., Dale C.J., Ranasinghe C., Stratov I., De Rose R., Chea S., et al. Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3. Vaccine 2005, 23:5009-5021.
42. + T cells. European Journal of Immunology 2011, 41:3513-3528.
43. + T cells. Proceedings of the National Academy of Sciences of the United States of America 2004, 1515(101):4-9.
44. Harari A., Bart P.A., Stohr W., Tapia G., Garcia M., Medjitna-Rais E., et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. Journal of Experimental Medicine 2008, 6(205):3-77.
45. Kerry S.E., Maile R., Collins E.J., Frelinger J.A. CD8 T cells require CD8 coreceptor engagement for calcium mobilization and proliferation, but not cytokine production. Immunology 2005, 114:44-52.
46. + T cells generated from CD28-deficient or wildtype mice exhibit a differential dependence on lipid raft integrity for activation. Cellular Immunology 2004, 14(227):8-55.
47. + T cell responses. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:11432-11437.
48. Vigano A., Principi N., Crupi L., Onorato J., Vincenzo Z.G., Salvaggio A. Elevation of IgE in HIV-infected children and its correlation with the progression of disease. Journal of Allergy and Clinical Immunology 1995, 95:627-632.
49. Ouaaz F., Ruscetti F.W., Dugas B., Mikovits J., Agut H., Debre P., et al. Role of IgE immune complexes in the regulation of HIV-1 replication and increased cell death of infected U1 monocytes: involvement of CD23/Fc epsilon RII-mediated nitric oxide and cyclic AMP pathways. Molecular Medicine 1996, 3(2):8-49.
50. Oettgen H.C. Regulation of the IgE isotype switch: new insights on cytokine signals and the functions of epsilon germline transcripts. Current Opinion in Immunology 2000, 12:618-623.